These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 9314610

  • 1. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB, Robinson BA.
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [Abstract] [Full Text] [Related]

  • 2. A sequential Bayesian algorithm for dose individualisation of carboplatin.
    Duffull SB, Begg EJ, Robinson BA, Deely JJ.
    Cancer Chemother Pharmacol; 1997 Sep; 39(4):317-26. PubMed ID: 9025772
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacokinetics and individual dose adjustment of carboplatin].
    Chatelut E, Canal P, Bugat R.
    Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ.
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [Abstract] [Full Text] [Related]

  • 7. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B, Boddy AV, Cole M, Pearson AD, Chatelut E, Rubie H, Newell DR.
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacokinetics of carboplatin.
    van der Vijgh WJ.
    Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
    Ghazal-Aswad S, Tilby MJ, Lind M, Baily N, Sinha DP, Calvert AH, Newell DR.
    Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
    Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ.
    J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
    [Abstract] [Full Text] [Related]

  • 12. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ, Errington J, Tilby MJ, Pearson AD, Foot AB, McDowell H, Ellershaw C, Pizer B, Nowell GM, Pearson DG, Boddy AV, UKCCSG Pharmacology Working Group.
    Br J Cancer; 2007 Mar 12; 96(5):725-31. PubMed ID: 17299395
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
    Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL.
    Cancer Chemother Pharmacol; 1999 Mar 12; 43(2):106-14. PubMed ID: 9923815
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Mar 12; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1997 May 12; 15(5):1953-64. PubMed ID: 9164207
    [Abstract] [Full Text] [Related]

  • 18. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
    Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R.
    J Clin Oncol; 1993 Jun 12; 11(6):1156-64. PubMed ID: 8501502
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
    van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, Beijnen JH.
    Semin Oncol; 1997 Feb 12; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.